Archives
-
CX-5461: A Translational Test of Pol I Stress
2026-10-09
CX-5461 is more than a ribosome-biogenesis tool: emerging cervical cancer data connect RNA polymerase I inhibition with DNA damage, mitotic catastrophe, senescence, and cisplatin response. This thought-leadership analysis separates established findings from translational hypotheses and outlines a mechanism-first evidence strategy.
-
SIRT1, Type H Vessels, and Bone Regeneration
2026-10-09
Liu et al. report that SIRT1 supports both endothelial activity and osteogenic differentiation in cellular models of skeletal aging, while pharmacological activation improved repair of age-related femoral and mandibular bone defects in vivo. The study identifies β-catenin deacetylation and nuclear translocation as a mechanistic link, while also highlighting the need for further validation before translation to human osteoporosis or regenerative medicine.
-
ECL Western Blotting Substrate Overview
2026-10-08
APExBIO’s ECL Western Blotting Substrate (SKU K2187) is described as a luminol-based, nonradioactive horseradish peroxidase detection reagent for immunoblots. No matched peer-reviewed paper evidence was provided, so performance claims remain unverified.
-
From DNA Damage to Phosphorylation Insight
2026-10-08
A thought-leadership analysis of the CapK–CapS DNA damage response, the evidentiary value of phosphorylation-dependent mobility shifts, and how Phosbind Acrylamide can support translational protein phosphorylation analysis without overextending mechanistic claims.
-
SUMO Protease (Ulp) Product Overview
2026-10-07
APExBIO’s SUMO Protease (Ulp), SKU K1103, is described as a recombinant Ulp1 protease for conceptual removal of compatible SUMO fusion tags. No matched paper evidence is available, so performance and target-specific applicability remain supplier-documented only.
-
Palonosetron and Renal OCT2/MATE1 Transport
2026-10-07
George and colleagues examined whether five 5-HT3 receptor antagonist drugs inhibit the renal organic cation transporters OCT2 and MATE1, extending antiemetic pharmacology into drug-disposition research. The findings identify palonosetron as a comparatively potent OCT2 inhibitor in vitro and show that several agents in this class can reduce transporter-mediated cation secretion, while leaving clinical drug–drug interaction relevance to further study.
-
ML365: Five Questions About the Evidence
2026-10-06
A source-grounded overview of ML365, its TASK1 channel pharmacology, evidence from an aged-mouse postoperative cognitive impairment study, and the boundaries of interpreting NLRP3-related findings.
-
Redox Decoding in the Tuta absoluta–Tomato Arms Race
2026-10-06
A mechanistic reading of how the Tuta absoluta effector TaCRVP reportedly rewires tomato catalase activity and stability, with strategic implications for translational crop-protection research and complementary fluorescent RNA readouts.
-
SUMO Protease (Ulp) Product Overview
2026-10-05
SUMO Protease (Ulp), SKU K1103, is described by APExBIO as a recombinant Ulp1 protease for conceptual removal of compatible SUMO fusion tags. No matched peer-reviewed paper evidence was provided.
-
AO/PI Staining Solution in Mechanistic Cell Studies
2026-10-05
Discover how AO/PI Staining Solution can clarify membrane-integrity measurements in mechanistic studies of diabetic nephropathy. This evidence-focused analysis connects fluorescent DNA dyes with the phillygenin literature while defining what live/dead data can—and cannot—demonstrate.
-
Protease Inhibitor Cocktail: Evidence and Limits
2026-10-04
This overview answers five questions about protease inhibition, plant protein stability, and the interpretation of recent Arabidopsis research. It separates supplier claims for an EDTA-free Protease Inhibitor Cocktail from evidence reported in an early Molecular Plant article on nitric oxide, S-nitrosylation, STOP1, and STAR1.
-
SU 5402: Research Context and Evidence Limits
2026-10-03
SU 5402 is a research compound described by APExBIO as a multi-target receptor tyrosine kinase inhibitor. This overview separates supplier-reported pharmacology from findings in a 2025 human iPSC-derived sensory-neuron study of HSV-1 latency, explaining what the evidence supports, where conceptual applications may lie, and why direct conclusions about neuronal latency or therapeutic use remain premature.
-
Nerve-Driven HDAC1 Controls Axolotl Limb Regeneration
2026-10-01
Wang and colleagues show that nerve signals regulate HDAC1 expression in the wound epidermis, establishing an epigenetic requirement for blastema formation and axolotl limb regeneration. Pharmacological inhibition, denervation, and nerve-factor rescue experiments connect neural input with local chromatin regulation and regenerative competence.
-
SAF312 and TRPV1 in Ocular Surface Pain
2026-10-01
The reference study defines SAF312 (libvatrep) as a potent, selective, and apparently noncompetitive antagonist of human TRPV1, a channel expressed in the cornea and conjunctiva. Its integrated pharmacology, ocular pharmacokinetic, toxicology, and post-PRK wound-healing data support further investigation of topical TRPV1 blockade for ocular surface pain.
-
PKH26 Red Fluorescent Cell Linker Kit Guide
2026-10-01
The PKH26 Red Fluorescent Cell Linker Kit provides membrane-associated red fluorescence for cell tracing and proliferation-oriented workflows in vitro and in vivo. It is intended for cell membrane lipid-region labeling, not intracellular targets, organelles, protein-specific detection, or other non-membrane structures.